FISCHER MEDICAL VENTURES LIMITED
(Formerly known as Fischer Chemic Limited)
Registered Office Address: Survey No. 480/2 AP Medtech Zone,
Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032
CIN: L86900AP1993PLC118162
Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548

November 14, 2026

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001.
BSE Scrip Code: 524743

National Stock Exchange of India Ltd.
Exchange Plaza, 5tll floor
Plot No. C/ 1, G Block,
Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051.
NSE Symbol: FISCHER

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 14th November, 2026

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (14/11/2026):

1. **Financial Results**

Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half year ended 30/09/2026 in the format specified under the SEBI (Listing Obligations and Disclosure Requirements) Regulations ,2015 ('SEBI Listing Regulations"), together with a copy of the Limited Review Reports of M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai for your records. The aforesaid Unaudited Financial Results are also uploaded on the Company's website www.fischermv.com.

An extract of the aforesaid Unaudited Financial Results, in the manner prescribed under the SEBI Listing Regulations, is annexed herewith in **Annexure-1** and the same will be published in English and Telugu newspapers within the time stipulated.

The Board Meeting commenced at 6:00 PM (IST) and concluded at 10:10 PM (IST)

Please take on record.

Thanking You,

Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

BALAJI GANDLA

Digitally signed by BALAJI GANDLA
Date: 2026.11.14 23:25:44 +05'30'

Fischer Medical Ventures Limited

BALAJI GANDLA
COMPANY SECRETARY AND COMPLIANCE OFFICER

FISCHER MEDICAL VENTURES LIMITED
CIN: L86900AP1993PLC118162

Regd Off: No.480/2, Andhra Pradesh Medtech Zone Limited, Nadapura Village, Pedagantyada Mandal, Nadupuru, Visakhapatnam, Andhra Pradesh, India, 530044
Corp off: Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006, India
Email: cs@fischermv.com | Website: www.fischermv.com

Unaudited Standalone and Consolidated Financial Results for the Quarter Ended 30.09.2026 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

Rs. In Lakhs

SL NO	PARTICULARS	STANDALONE						CONSOLIDATED					
		Quarter Ended			Half Year Ended		Year Ended	Quarter Ended			Half Year Ended		Year Ended
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue From Operations	**27.62**	72.17	742.69	**99.79**	1,196.92	1,739.18	**10,743.65**	8,192.00	8,629.52	**18,935.64**	10,984.53	30,857.56
II	Other Income	**3,037.72**	89.06	143.46	**3,126.78**	223.86	349.34	**458.17**	148.43	248.14	**606.60**	994.78	1,231.37
III	Total Income (I + II)	**3,065.34**	**161.23**	**886.15**	**3,226.57**	**1,420.78**	**2,088.52**	**11,201.82**	**8,340.43**	**8,877.65**	**19,542.24**	**11,979.31**	**32,088.93**
IV	Expenses												
	Cost of Materials Consumed	**-**	-	-	**-**	-	-	**1,350.05**	1,561.29	6,134.03	**2,911.34**	6,134.03	10,645.87
	Purchase of Stock-In-Trade	**349.05**	75.50	463.47	**424.55**	782.06	1,195.68	**7,327.05**	4,268.01	35.16	**11,595.07**	793.16	8,976.02
	Changes In Inventories of Finished Goods, Work-In-Progress And Stock-In-Trade	**(287.56)**	(7.78)	-	**(295.34)**	-	(35.45)	**(287.56)**	(7.78)	-	**(295.34)**	496.32	(62.87)
	Employee Benefits Expense	**65.10**	56.43	45.46	**121.54**	87.22	201.51	**572.07**	452.35	374.75	**1,024.42**	694.33	1,509.42
	Direct Expenses	**-**	-	-	**-**	-	-	**-**	-	-	**-**	-	-
	Finance Costs	**128.60**	147.32	111.77	**275.92**	242.65	465.23	**342.99**	354.30	91.87	**697.29**	158.91	583.40
	Depreciation and Amortisation Expenses	**77.99**	76.74	8.16	**154.73**	16.32	67.86	**134.02**	136.04	51.37	**270.06**	128.34	297.93
	Other Expenses	**124.40**	136.00	119.47	**260.41**	176.26	1,244.27	**887.94**	793.00	465.07	**1,680.94**	811.60	5,480.78
	Total Expenses	**457.59**	**484.22**	**748.33**	**941.80**	**1,304.51**	**3,139.11**	**10,326.56**	**7,557.21**	**7,152.25**	**17,883.77**	**9,216.69**	**27,430.55**
V	Profit / (Loss) Before Exceptional Items & Tax (III - IV)	**2,607.75**	**(322.99)**	**137.82**	**2,284.77**	**116.27**	**(1,050.58)**	**875.26**	**783.21**	**1,725.40**	**1,658.48**	**2,762.64**	**4,658.38**
VI	Share of Profit / (Loss) of Associates	**-**	**-**	**-**	**-**	**-**	**-**	**-**	-	**(4.22)**	**-**	**(15.37)**	**(22.19)**
VII	Exceptional Items	**-**	-	-	**-**	-	-	**-**	-	-	**-**	-	-
VIII	Profit / (Loss) Before Tax (V - VI)	**2,607.75**	**(322.99)**	**137.82**	**2,284.77**	**116.27**	**(1,050.58)**	**875.26**	**783.21**	**1,721.18**	**1,658.48**	**2,747.26**	**4,636.19**
IX	Tax Expense												
	Current Tax	**(472.00)**	-	-	**(472.00)**	-	(9.00)	**(748.53)**	(242.86)	(275.14)	**(991.39)**	(716.76)	(1,722.88)
	Deferred Tax Expenses	**(78.03)**	(27.42)	(54.05)	**(105.45)**	(93.44)	17.29	**(46.27)**	(161.22)	(61.47)	**(207.49)**	(136.57)	129.08
	Tax pertaining to Previous year	**-**	-	-	**-**	-	-	**-**	-	-	**-**	-	(9.00)
	Minimum Alternate Tax												68.55
X	Profit / (Loss) For The Period From Continuing Operations (VII - VIII)	**2,057.72**	**(350.41)**	**83.77**	**1,707.32**	**22.83**	**(1,042.29)**	**80.45**	**379.14**	**1,384.57**	**459.59**	**1,893.95**	**3,101.95**
XI	Profit / (Loss) From Discontinued Operations	**-**	-	-	**-**	-	-	**-**	-	-	**-**	-	-
XII	Tax Expense of Discontinued Operations	**-**	-	-	**-**	-	-	**-**	-	-	**-**	-	-
XIII	Profit / (Loss) From Discontinued Operations After Tax (X - XI)	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**-**
XIV	Profit / (Loss) For The Period (IX + XII)	**2,057.72**	**(350.41)**	**83.77**	**1,707.32**	**22.83**	**(1,042.29)**	**80.45**	**379.14**	**1,384.57**	**459.59**	**1,893.95**	**3,101.95**
XV	Other Comprehensive Income												
	Items That Will Not Be Reclassified To Profit / (Loss)	**(3.04)**			**(3.04)**			**0.16**			**0.16**		
	(i) Remeasurement of Defined Benefit Plan - Actuarial Gains / (Losses)	**-**	-	-	**-**	-	-	**-**	-	6.32	**-**	6.32	5.43
	(ii) Income Tax Relating on Above	**(0.77)**	-	-	**(0.77)**	-	-	**(0.77)**	-	-	**(0.77)**	-	-
	(iii) Equity Instruments Through Other Comprehensive Income	**-**	-	-	**-**	-	-	**-**	-	**-**	**-**	-	-
	Other Comprehensive Income - Total	**(3.81)**	**-**	**-**	**(3.81)**	**-**	**-**	**(0.61)**	**-**	**6.32**	**(0.61)**	**6.32**	**5.43**
XVI	Total Comprehensive Income For The Period (Comprising Profit / (Loss) For The Period (After Tax) And Other Comprehensive Income For The Period (After Tax))	**2,053.92**	**(350.41)**	**83.77**	**1,703.51**	**22.83**	**(1,042.29)**	**79.85**	**379.14**	**1,390.89**	**458.99**	**1,900.27**	**3,107.38**
XVII	Paid Up Equity Share Capital (Face Value Re.1/-)	**6,986.85**	6,545.15	6,485.15	**6,986.85**	6,485.15	6,545.15	**6,986.85**	6,545.15	6,485.15	**6,986.85**	6,485.15	6,545.15
XVIII	Other Equity						24,684.13						29,309.40
XIX	Earnings Per Share (EPS) (a) Basic EPS From Continuing Operations (In Rs.)	**0.31**	(0.05)	0.13	**0.26**	0.04	(0.16)	**0.01**	0.06	2.15	**0.07**	2.92	0.47
	(c) Diluted EPS From Continuing Operations (In Rs.)	**0.31**	(0.05)	0.13	**0.26**	0.03	(0.15)	**0.01**	0.05	2.11	**0.07**	2.87	0.44

// BY ORDER OF THE BOARD //

For and on Behalf of the Board
Fischer Medical Ventures Limited
(formerly known as Fischer Chemic Limited)

Ravindran Govindan
Chairman & Managing Director
DIN: 03137661

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)


We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Company') for the quarter ended 30th September 2026 and for the year to date results for the period 1 April 2026 to 30 September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

1. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India, A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bilimoria Mehta & Co,
Chartered Accountants
FRN.: 101490W





CA Aakash Mehta
Partner
Membership No: 165824
Place: Mumbai
Date: November 14, 2026
UDIN: 26165824UYCKJF1475

Fischer Medical Ventures Limited

CIN : L86900AP1993PLC118162

STATEMENT OF STANDALONE UNAUDITED BALANCE SHEET AS AT SEPTEMBER 2026

(Amount in lakhs)

Particulars	As At September 30, 2026	As At March 31, 2026
	(Unaudited)	(Audited)
Assets		
(1) Non-Current Assets		
(a) Property,plant and equipment	1,304.57	1,136.24
(b) Financial Assets		
(i) Investments	35,604.61	30,354.97
(ii) Other Financial Asset	4,077.89	4,317.80
(c) Deferred Tax Asset (Net)	-	44.92
(d) Other Non Current Assets	142.60	53.29
Total Non-Current Assets	**41,129.67**	**35,907.22**
(2) Current assets		
(a) Inventories	337.29	41.95
(b) Financial assets		
(i) Trade receivables	1,693.42	2,071.01
(ii) Cash and cash equivalents	2,651.78	113.85
(iii) Loans	-	-
(iv) Other Financial Assets	3,234.04	203.83
(c) Current Tax Asset(Net)	-	9.15
(d) Other Current Assets	3,416.50	518.13
Total Current Assets	**11,333.02**	**2,957.92**
Total Assets	**52,462.69**	**38,865.14**
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	6,986.85	6,545.15
(b) Other Equity	36,276.90	27,268.08
Total Equity	**43,263.76**	**33,813.23**
Liabilities		
(1) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	2,445.00	1,296.96
(ii) Lease Liabilities	2,130.51	2,559.81
(b) Provisions	15.86	10.40
(c) Deferred tax liability (net)	61.30	-
Total Non-Current Liabilities	**4,652.66**	**3,867.17**
(2) Current Liabilities		
(a) Financial Liabilities		
Borrowings		
Lease Liabilities	1,089.03	708.00
Trade payables		
total outstanding dues of micro enterprises and small enterprises	273.30	219.60
total outstanding dues of creditors other than micro enterprises and small enterprises	62.19	144.82
Other Financial liabilities	2,641.84	69.52
(b) Other Current Liabilities	142.75	29.71
(c) Provisions	40.91	13.08
(d) Current Tax Liability (Net)	296.24	-
Total Current Liabilities	**4,546.27**	**1,184.73**
Total Equity and Liabilities	**52,462.69**	**38,865.14**

For M/s Billimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

CA Akash Mehta
Partner
M.No: 030382
Date: 14.11.2026
Place of Signature : Mumbai

For and on behalf of the Board of Directors

Ravindran Govindan
Chairman and Managing Director
DIN: 03137661

Fischer Medical Ventures Limited

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)
CIN : L86900AP1993PLC118162
STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(Amount in lakhs)

	Particulars	Quarter ended			Half Year ended		Year ended
		September 30, 2026	June 30, 2026	September 30, 2025	September 30, 2026	September 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)
	Income						
I)	**Revenue From Operations**	27.62	72.17	742.69	99.79	1,196.92	1,739.18
II)	**Other Income**	3,037.72	89.06	143.46	3,126.78	223.86	349.34
III)	**Total Income (I+II)**	**3,065.34**	**161.23**	**886.15**	**3,226.57**	**1,420.78**	**2,088.52**
	Expenses :						
	Purchase of Traded Goods	349.05	75.50	463.47	424.55	782.06	1,195.68
	Changes in inventories of finished goods, by-products and work in progress	(287.56)	(7.78)		(295.34)	-	(35.45)
	Employee Benefit expenses	65.10	56.43	45.46	121.54	87.22	201.51
	Finance Cost	128.60	147.32	111.77	275.92	242.65	465.23
	Depreciation and Amortization Expenses	77.99	76.74	8.16	154.73	16.32	67.86
	Other Expenses	124.40	136.00	119.47	260.41	176.26	1,244.27
IV)	**Total Expenses (IV)**	**457.59**	**484.22**	**748.33**	**941.80**	**1,304.51**	**3,139.11**
V)	**Profit (Loss) Before exceptional and tax (III-IV)**	**2,607.75**	**(322.99)**	**137.82**	**2,284.77**	**116.27**	**(1,050.58)**
VI)	Exceptional Items					-	-
VII)	**Profit before tax (V-VI)**	**2,607.75**	**(322.99)**	**137.82**	**2,284.77**	**116.27**	**(1,050.58)**
VIII)	Tax Expenses						
	i) Current Tax	(472.00)			(472.00)	-	-
	ii) Deferred Tax	(78.03)	(27.42)	(54.05)	(105.45)	(93.44)	17.29
	iii) Tax pertaining to previous year					-	(9.00)
IX)	**Profit (Loss) from Continuing Operations (VII-VIII)**	**2,057.72**	**(350.41)**	**83.77**	**1,707.32**	**22.83**	**(1,042.29)**
X)	**Other Comprehensive income;**						
	(i) Items that will not be reclassified to profit or loss	(3.04)	-	-	(3.04)	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.77)	-	-	(0.77)	-	-
	(iii) Items that will be reclassified to profit or loss						
	(iv) Income tax relating to items that will be reclassified to profit or loss						
XI)	**Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (IX-X)**	**2,053.92**	**(350.41)**	**83.77**	**1,703.51**	**22.83**	**(1,042.29)**
XII)	Paid up Equity Share Capital (Face Value Re.1/-)	6,986.85	6,545.15	6,481.15	6,986.85	6,481.15	6,545.15
XIII)	**Earnings per Equity Shares**						
	1) Basic	**0.31**	**(0.05)**	**0.13**	**0.26**	**0.04**	**(0.16)**
	2) Diluted	**0.31**	**(0.05)**	**0.13**	**0.26**	**0.03**	**(0.15)**

The accompanying notes are an integral part of the financial statements.
As per report of even date.

For M/s Billimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

CA Akash Mehta
Partner
M.No: 030382
Date: 14.11.2026
Place of Signature : Mumbai

For and on behalf of the Board of Directors

Ravindran Govindan
Chairman and Managing Director
DIN: 03137661

Fischer Medical Ventures Limited

FISCHER MEDICAL VENTURES LIMITED

CIN: L86900AP1993PLC118162

STATEMENT OF STANDALONE UNAUDITED CASH FLOWS FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2026

(Amount in lakhs)

Particulars	For the Half Year ended 30 September 2026	For the Half Year ended 30 September 2025
	(Unaudited)	(Unaudited)
A. CASH FLOWS FROM OPERATING ACTIVITIES		
Net Profit Before Tax	2,284.77	116.27
Adjustments for:		
Add: Depreciation on Right of use	134.63	16.32
Add: Deffered Rent	20.10	-
Add: Interest on Borrowings	94.87	-
Add: Interest and finance charges	-	242.65
Add: Interest on Lease liability	158.83	-
Add: Provision for expected credit loss	18.37	-
Add: Provision for Gratuity	2.45	-
Less: Interest on Fixed Deposit	(78.49)	-
Less: Interest on Security Deposit	(16.91)	-
Less: Interest on Net-investment	(51.04)	-
Less: Interest income	-	(223.86)
Less: Dividend income	(2,704.83)	
Operating Profit Before Working Capital Changes	**(137.25)**	**151.38**
Movements in working capital:		
(Increase) / Decrease in inventories	(295.34)	-
(Increase) / Decrease in trade receivables	359.22	(427.10)
(Increase) / Decrease in other current financial assets	(77.02)	545.80
(Increase) / Decrease in other current assets	(2,898.38)	(207.25)
(Increase) / Decrease in other non-current assets	(109.41)	
(Increase) / Decrease in other non current financial assets	(122.93)	(454.44)
Increase / (Decrease) in trade payables	(28.93)	240.32
Increase / (Decrease) in other financial liabilities	(8.71)	124.06
Increase / (Decrease) in short-term provisions	22.33	0.50
Increase / (Decrease) in non-current provisions	5.45	5.28
Increase / (Decrease) in other current liabilities	113.05	12.07
Net Working Capital Changes	**(3,040.66)**	**(160.77)**
Cash Generated from / (Used in) Operations	**(3,177.90)**	**(9.39)**
Less: Income taxes paid (net of refunds)	(166.61)	
A. NET CASH FROM / (USED IN) OPERATING ACTIVITIES	**(3,344.51)**	**(9.39)**
B. CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(2.63)	0.00
Investment in subsidiaries	(2,668.61)	(920.18)
(Investment in) / Proceeds from fixed deposits	(60.00)	-
Receipts from net investment in sublease	77.44	-
Interest income	78.49	220.57
Dividend received from subsidiary	165.00	-
B. NET CASH FROM / (USED IN) INVESTING ACTIVITIES	**(2,410.31)**	**(699.61)**
C. CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from issue of equity shares on conversion of warrants	7,751.84	261.45
Proceeds from / (Repayment of) long-term borrowings (net)	1,148.04	1,531.38
Repayment of lease liabilities	(507.43)	(287.13)
Interest and other finance costs paid	(94.87)	-
Dividends paid	(4.82)	
C. NET CASH FROM / (USED IN) FINANCING ACTIVITIES	**8,292.75**	**1,505.70**
D. NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+	**2,537.93**	**796.70**
E. Opening Cash and Cash Equivalents	113.85	28.71
F. Closing Cash and Cash Equivalents	**2,651.78**	**825.41**

Note: The cash flow statement is prepared using the indirect method set out in IND AS 7 - Statement of Cash Flow

For M/s Billimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

CA Akash Mehta
Partner
M.No: 030382
Date: 14.11.2026
Place of Signature : Mumbai

For and on behalf of the Board of Directors

Ravindran Govindan
Chairman and Managing Director
DIN: 03137661

Fischer Medical Ventures Limited

Notes to Financial Statements:

1. The unaudited financial results of the Group for the quarter and half year ended September 30, 2026 have been prepared in accordance with the Indian Accounting Standards ("Indian Accounting Standards ("Ind As") As Prescribed under section 133 of the Companies Act, 2013 as amended.

2. The unaudited financial results of the Group for the quarter/half year ended September 30, 2026 have been reviewed by the audit committee on November 14, 2026 and thereafter Board of directors at their meeting held on November 14, 2026.

3. The Group is primarily engaged in one business segment in accordance with the requirement of Indian Accounting Standards (Ind As) 108: Operating Segment. Accordingly, no separate segment information has been provided.

4. On 28th July, 2025, the Board approved the sub division of Equity shares of Rs. 10/- into 10 equity shares of Re.1 /- each by amending the capital clause of the Memorandum of Association. The shareholder's approval was obtained via postal Ballot on 30th August, 2025. Effective from the record date of 12th September, 2025, the authorized and paid-up share capital of the Company was split accordingly. Earnings Per Share (EPS) for the current and comparative periods has been proportionately adjusted and restated to ensure consistency and comparability.

5. During the quarter, the Company's Board of Directors, through Circular Resolutions dated August 11, August 12, August 13 and August 14 2026, approved the allotment of equity shares upon conversion of convertible warrants, pursuant to the exercise of the conversion option by the respective warrant holders.

   The details of the allotments are as follows:

   • 11 August 2026: The Board approved the allotment of 23,00,000 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹4,03,65,000.

   • 12 August 2026: The Board approved the allotment of 66,31,664 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹11,63,85,703.

   • 13 August 2026: The Board approved the allotment of 1,42,78,217 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by persons belonging to the Promoter and Non-Promoter Categories. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹25,05,82,708.35.

   • 14 August 2026: The Board approved the allotment of 2,05,05,909 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by persons belonging to the Promoter and Non-Promoter Categories. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹35,98,78,702.95.

•17 August 2026: The Board approved, through a circular resolution, the allotment of 4,54,210 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹79,71,385.50.

6. Figures for the previous periods have been reclassified, wherever necessary, to conform to the current period's classification.

7. Changes in Comparative Figures: -

The consolidated comparative figures for the quarter and half-year ended September 30, 2025, in respect of FMV International Ventures PTE Ltd., Fischer Hospitality Sdn. Bhd., FMV Global Innovations PTE Ltd., PellucidCare Health Innovations Pte Ltd. (formerly known as FMV HealthCare PTE Ltd.) (foreign subsidiaries) and one foreign step-down subsidiary, FMV Technologies Sdn. Bhd., were initially considered based on financial information certified by the respective management, as these subsidiaries were not material individually or in aggregate for the purpose of quarterly consolidation.

Subsequently, the respective component auditors, while completing the annual audit of these foreign subsidiaries for the previous financial year, identified and incorporated certain audit adjustments relating to the financial information of the previous year. These adjustments were made to appropriately reflect the financial information on a quarterly basis and ensure comparability of the financial figures. The component auditors have subsequently provided their review deliverables for Q2 FY 2026-27, incorporating the revised comparative financial figures based on the audited financial information.

Accordingly, the comparative figures for the quarter ended September 30, 2025, and the corresponding half-year period ended September 30, 2025, have been revised in the consolidated financial statements to reflect the financial information provided by the component auditors. Consequently, certain comparative figures previously reported in the consolidated financial statements differ from the corresponding figures presented in the current period.

These revisions arise from the incorporation of audit adjustments identified during the subsequent annual audit of the foreign subsidiaries and do not have any impact on the overall annual profit/(loss) or closing reserves of the Group for the previous financial year.

Details of the revisions are disclosed below for transparency and to facilitate an appropriate understanding and comparison of the financial information.

(Amount in Lakhs)

Particulars	**Variance**	
	Quarter ended September 30, 2025	**Year to Date period ended September 30, 2025**
Sales	(1.01)	9.54
Total Income (A)	**(1.01)**	**9.54**
Cost of Material Consumed	5.67	5.67
Employee Benefit Expenses	-	3.80
Finance Costs	-	0.05
Other Expenses	(1.67)	18.58
Total Expenses (B)	**4.00**	**28.10**
Net Profit (A-B)	**(5.01)**	**(18.55)**

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30 September 2026 and consolidated year to date results for the period 1 April 2026, to 30 September 2026, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1 /44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial results of subsidiaries included in the Statement, whose financial information reflects total assets (before elimination) of Rs 66,068.90 Lakhs as at 30 September 2026, and year-to-date total revenue from operation (before elimination) of Rs 18,890.39 lakhs and year-to-date total comprehensive income (before elimination) of Rs1,482.02 lakhs, as considered in the Statement, in respect of an associate, whose interim financial results have not been reviewed by us. These interim financial results have been reviewed by other auditors whose review reports have been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate is based solely on the review report of such other auditors.

7. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of Step-down Subsidiary, whose unaudited interim financial result includes total assets (before elimination) of Rs 740.33 Lakhs, year-to-date revenue from operation (before elimination) of Rs. 525.22 Lakhs, year-to-date net loss after tax (before elimination) of Rs. 17.79 Lakhs, and year to-date total comprehensive loss (before elimination) of Rs. 17.79 Lakhs, for the half year ended September 30, 2026 which has not been reviewed by any auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the Associate, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group. Our conclusion on the statement in respect of matter stated above is not modified with respect to the financial result certified by the management.

   Further, these subsidiaries and an associate, which are located outside India, whose interim financial results have been prepared in accordance with accounting principles generally accepted in their respective country and which have been reviewed by the other auditors under International Standards on Review Engagements (ISRE). The Holding Company's management has converted the financial results of such subsidiaries and an associate from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Holding Company's management. Our conclusion, in so far as it relates to the balances and affairs of these subsidiaries and an associate is based on the review reports of the other auditors and the conversion adjustments prepared by the management of the Holding Company and reviewed by us.

   Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

   Emphasis of Matter


   We draw attention to Note No.7 to the consolidated financial statements, which describes the revision of the comparative figures for the quarters ended September 30, 2025 and year to date period ended September 30, 2025 in respect of certain foreign subsidiaries. The comparative financial information for the quarter ended September 30, 2025 and year to date period ended September 30, 2025 was initially considered based on financial information provided and certified by the respective management, as the respective subsidiaries were not material individually or in aggregate for the purpose of quarterly consolidation.

   Subsequently, during the annual audit of the respective foreign subsidiaries, the component auditors identified and incorporated certain audit adjustments relating to the quarterly financial information of the previous year. The revised quarterly financial information, incorporating such audit adjustments, was subsequently provided by the component auditors as part of their review deliverables for Q2 FY 2026-27.

Accordingly, the comparative figures for the aforesaid quarters have been revised in the current consolidated financial statements to reflect the financial information provided by the component auditors. As a result, certain comparative figures previously reported in the consolidated financial statements differ from the corresponding figures presented in the current period. These revisions arise from the incorporation of audit adjustments identified during the subsequent annual audit of the foreign subsidiaries and do not affect the overall annual profit/(loss) or closing reserves of the Group for the previous financial year. A detailed reconciliation is also being disclosed in the Note No.7 of the consolidated financials.

Our conclusion is not modified in respect of this matter.

For Bilimoria Mehta & Co,
Chartered Accountants
ICAI Firm Registration No.: 101490W





CA Aakash Mehta
Partner
Membership No: 165824
Place: Mumbai
Date: November 14, 2026
UDIN: 26165824XPLLCG3636

ANNEXURE-1

List of Entities included in the statement:

Sr no	Particulars	Stakes	Status	Auditor
1	Time Medical International Ventures (India) Private Limited	100%	Subsidiary	Reviewed by SMPB & Co.
2	Time Medical Philippines (Subsidiary of Time Medical International Ventures (India) Private Limited)	75%	Subsidiary	Reviewed by VIOLETA L.ABAD, C.P.A..
3	Blusim tech Pte Ltd. (Singapore)	20%	Associate of (Time Medical)	Reviewed by SMPB & Co.
4	The Therapy Platform Pte Ltd (Singapore)	20%	Associate of (Time Medical)	Reviewed by SMPB & Co.
5	Flynncare HealthCare Innovations Private Limited	100%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by SMPB & Co.
6	Wondertech Medical Solutions Pvt Ltd	51%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by SMPB & Co.
7	Nanyang Biologics (India) Private Limited	51%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by SMPB & Co.
8	Fischer Hospitality Sdn. Bhd.	60%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by GW & Co.
9	FMV International Ventures PTE Ltd.	100%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by LL Ong & Co.
10	FMV Global Innovations PTE Ltd	100%	Subsidiary of Fischer Medical Ventures Limited	Reviewed by LL Ong & Co.
11	FMV Technologies Sdn Bhd	100%	Step- down subsidiary of Fischer Medical Ventures Limited	Reviewed by GW & Co.
12	PellucidCare Health Innovations Pte Ltd (Formerly known as FMV HealthCare PTE Ltd)	100%	Step- down subsidiary of Fischer Medical Ventures Limited	Reviewed by LL Ong & Co.
13	PT Fischer Pariko Medical Ventures	70%	Step- down subsidiary of Fischer Medical Ventures Limited	Unaudited

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN : L86900AP1993PLC118162

UNAUDITED CONSOLIDATED BALANCE SHEET AS AT SEPTEMBER 30, 2026

(Amount in lakhs)

Particulars	As At September 30, 2026	As At March 31, 2026
	(Unaudited)	(Audited)
Assets		
(1) Non-Current Assets		
(a) Property,plant and equipment	3,701.46	2,639.54
(b) Intangible Asset	150.06	
(c) Capital work-in-progress	209.96	293.40
(d) Financial Assets	-	
Investments	12,039.55	11,770.96
Other Financial Asset	-	
Loans	-	
Others	4,929.90	5,094.87
(e) Deferred Tax Asset (Net)	96.92	204.86
(f) Other Non Current Assets	286.88	4,811.00
(g) Goodwill	527.70	527.70
Total Non-Current Assets	**21,942.43**	**25,342.34**
(2) Current assets		
(a) Inventories	2,558.64	1,266.32
(b) Financial assets	-	
Investments		
Trade receivables	30,435.14	28,879.80
Cash and cash equivalents	7,351.61	1,188.94
Bank balances other than cash and cash equivalents	282.45	1,315.64
Loans	128.21	128.00
Other Financial Asset	886.65	522.32
(c) Current Tax Asset(Net)	(162.83)	9.15
(d) Other Current Assets	11,592.90	8,448.53
Total Current Assets	**53,072.77**	**41,758.71**
Total Assets	**75,015.20**	**67,101.05**
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	6,986.86	6,545.15
(b) Other Equity	39,512.49	31,735.45
(c) Non Controlling Interest	83.87	86.90
(d) Money Received Against Share Warrants	-	
(d) FCTR	79.92	146.72
Total Equity	**46,663.15**	**38,514.22**
Liabilities		
(1) Non-Current Liabilities		
(a) Financial Liabilities		
Borrowings	1,541.21	26.09
Lease Liabilities	2,133.99	2,659.41
Other Financial Liabilities	-	
(b) Deferred Tax Liability	100.31	
(c) Other Non Current Liabilities	443.32	
(d) Provisions	185.45	98.75
Total Non-Current Liabilities	**4,404.29**	**2,784.25**
(2) Current Liabilities		
(a) Financial Liabilities		
Borrowings	3,684.16	7,209.92
Lease Liabilities	1,168.82	812.11
Trade payables	-	
total outstanding dues of micro enterprises and small enterprises	640.94	1,002.84
total outstanding dues of creditors other than micro enterprises and small enterprises	11,881.87	9,257.53
Other Financial liabilities	399.11	116.94
(b) Other Current Liabilities	955.74	1,342.09
(c) Provisions	2,745.94	4,310.70
(d) Current Tax Liability (Net)	2,471.25	1,750.45
Total Current Liabilities	**23,947.83**	**25,802.58**
Total Equity and Liabilities	**75,015.20**	**67,101.05**

For M/s Billimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

CA Akash Mehta
Partner
M.No: 030382
Date: 14.11.2026
Place of Signature : Mumbai

For and on behalf of the Board of Directors

Ravindran Govindan
Chairman and Managing Directo
DIN: 03137661

Fischer Medical Ventures Limited

Fischer Medical Ventures Limited
CIN : L86900AP1993PLC118162
UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2026

(Amount in lakhs)

	Particulars	Quarter ended			Half Year ended		Year ended
		September 30, 2026	June 30, 2026	September 30,2025	September 30, 2026	September 30,2025	March 31, 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Income						
I)	**Revenue From Operations**	10,743.65	8,192.00	8,629.52	18,935.64	10,984.53	30,857.56
II)	**Other Income**	458.17	148.43	248.14	606.60	994.78	1,231.37
III)	**Total Income (I+II)**	**11,201.82**	**8,340.43**	**8,877.65**	**19,542.24**	**11,979.31**	**32,088.93**
	Expenses :						
	Cost of Material Consumed	1,350.05	1,561.29	6,134.03	2,911.34	6,134.03	10,645.87
	Purchase of Traded Goods	7,327.05	4,268.01	35.16	11,595.07	793.16	8,976.02
	Changes in inventories of finished goods, by-products and work in progress	(287.56)	(7.78)	-	(295.34)	496.32	(62.87)
	Direct Expenses	-	-	-	-	-	
	Employee Benefit expenses	572.07	452.35	374.75	1,024.42	694.33	1,509.42
	Finance Cost	342.99	354.30	91.87	697.29	158.91	583.40
	Depreciation and Amortization Expenses	134.02	136.04	51.37	270.06	128.34	297.93
	Other Expenses	887.94	793.00	465.07	1,680.94	811.60	5,480.78
IV)	**Total Expenses (IV)**	**10,326.56**	**7,557.21**	**7,152.25**	**17,883.77**	**9,216.69**	**27,430.55**
V)	**Profit (Loss) Before exceptional and tax (III-IV)**	**875.26**	**783.21**	**1,725.40**	**1,658.48**	**2,762.64**	**4,658.38**
VI)	**Profit before tax (V-VI)**	**875.26**	**783.21**	**1,725.40**	**1,658.48**	**2,762.64**	**4,658.38**
VII)	Share of Loss from Associate				-	-	-
	- The Therapy Platform Pte Ltd	-		(4.15)	-	(4.04)	(3.87)
	- Bluesim tech pte ltd FS	-		(0.07)	-	(11.33)	(18.32)
	Profit/(loss) before exceptional items and tax (VII + VIII)	**875.26**	**783.21**	**1,721.18**	**1,658.48**	**2,747.26**	**4,636.19**
VI)	Exceptional Items			-	-		-
VII)	**Profit before tax (V-VI)**	**875.26**	**783.21**	**1,721.18**	**1,658.48**	**2,747.26**	**4,636.19**
VIII)	Tax Expenses						
	i) Current Tax	(748.53)	(242.86)	(275.14)	(991.39)	(716.76)	(1,722.88)
	ii) Deferred Tax	(46.27)	(161.22)	(61.47)	(207.49)	(136.57)	129.08
	iii) Tax pertaining to previous year		-		-		(9.00)
	iv) Minimum Alternate Tax		-		-		68.55
IX)	**Profit (Loss) from Continuing Operations (VII-VIII)**	**80.45**	**379.14**	**1,384.57**	**459.59**	**1,893.95**	**3,101.95**
X)	Profit (Loss) from Discontinuing Operations						-
XI)	Tax Expenses for Discontinuing Operations						-
XII)	Profit (Loss) from Discontinuing Operations (After Tax) (X-XI)						-
XIII)	Profit (Loss) for the period (XI+XII)	**80.45**	**379.14**	**1,384.57**	**459.59**	**1,893.95**	**3,101.95**
X)	**Other Comprehensive income;**						
	(i) Items that will not be reclassified to profit or loss	0.16		6.32	0.16	6.32	5.43
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(0.77)			(0.77)	-	
	(iii) Items that will be reclassified to profit or loss	-			-	-	
	(iv) Income tax relating to items that will be reclassified to profit or loss				-	-	
XI)	**Total Comprehensive Income for the period (Comprising profit/ (loss) and other Comprehensive Income for the period (IX-X)**	**79.85**	**379.14**	**1,390.89**	**458.99**	**1,900.27**	**3,107.38**
	Net Profit attributable to						
	a) Owners of the Company				**490.10**		
	b) Non-Controlling Interest				**(31.11)**		
XII)	Paid up Equity Share Capital (Face Value Re.1/-)	6,986.85	6,545.15	6,485.15	6,986.85	6,485.15	6,545.15
XIII)	**Earnings per Equity Shares**						
	1) Basic	**0.01**	**0.06**	**2.15**	**0.07**	**2.92**	**0.47**
	2) Diluted	**0.01**	**0.05**	**2.11**	**0.07**	**2.87**	**0.44**

For M/s Billimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

CA Akash Mehta
Partner
M.No: 030382
Date: 14.11.2026
Place of Signature : Mumbai

For and on behalf of the Board of Directors

Ravindran Govindan
Chairman and Managing Director
DIN: 03137661

Fischer Medical Ventures Limited

FISCHER MEDICAL VENTURES LIMITED

CIN: L86900AP1993PLC118162

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE QUARTER ENDED 30th SEPTEMBER 2026

(Amount in lakhs)

Particulars	30 September 2026	30 September 2025
	(Unaudited)	(Unaudited)
A. CASH FLOWS FROM OPERATING ACTIVITIES		
Net Profit Before Tax attrituable to Owner	1,662.26	2,767.71
Adjustments for non-cash and non-operating items:		
Add: Depreciation and Amortization	107.88	128.34
Add: Depreciation on Right of use	180.90	-
Add: Deffered Rent	94.87	-
Add: Interest on Borrowings	656.01	-
Add: Interest on Lease liability	165.16	-
Add: Provision for Gratuity & Leave Encashment	10.74	-
Add: Finance Costs	-	158.86
Add: : Provision for expected credit loss	304.56	-
Less: Interest on Fixed Deposit	(65.58)	-
Less: Interest on loans	298.24	-
Less: Interest on Security Deposit	(16.91)	-
Less: Interest on Net-investment	(86.87)	-
Operating Profit Before Working Capital Changes	**3,311.27**	**3,054.91**
Movements in Working Capital:		
(Increase) / Decrease in Trade Receivables	(1,859.91)	(8,620.11)
(Increase) / Decrease in Inventories	(1,292.31)	391.53
(Increase) / Decrease in Other Current Assets	(3,205.14)	(297.29)
(Increase) / Decrease in Other Non Current Assets	3,442.50	(897.21)
(Increase) / Decrease in Other Current Financial Assets	(645.86)	(2,124.86)
(Increase) / Decrease in Other Non Current Financial Assets	164.98	(542.60)
Increase / (Decrease) in Trade Payables	2,262.45	2,210.44
Increase / (Decrease) in Other Financial Liabilities	282.17	155.61
Increase / (Decrease) in Short-Term Provisions	(1,575.50)	(29.73)
Increase / (Decrease) in Other Current Liabilities	(386.35)	387.53
Increase / (Decrease) in Current Lease Liablities	-	(690.12)
Increase / (Decrease) in Non Current Liabilities	443.32	
Increase / (Decrease) in Non-Current Provisions	86.71	0.15
Net Working Capital Changes	**(2,282.96)**	**(10,056.66)**
Net Cash Generated from / (Used in) Operations	**1,028.30**	**(7,001.76)**
Less: Taxes Paid/ Received	(98.62)	52.41
A. NET CASH FROM / (USED IN) OPERATING ACTIVITIES	**929.69**	**(6,949.35)**
B. CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of Property, Plant & Equipment (net)	(1,116.27)	(831.64)
Purchase of Investments in Subsidiaries / Others (net)	(268.59)	(11,023.53)
Refund of Capital advance	-	2,000.00
(Net investment in) / Proceeds from Fixed Deposits	986.75	-
(Net investment in) / Proceeds from lease Investment	86.87	-
Interest and Other Income Received (cash basis)	65.58	-
B. NET CASH FROM / (USED IN) INVESTING ACTIVITIES	**(245.66)**	**(9,855.17)**
C. CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from Money received - Share Capital	7,751.84	260.96
Lease Liability	(634.91)	366.51
Proceeds from Long-Term Borrowings	1,515.11	(4,671.65)
Proceeds from Short-Term Borrowings	(3,525.76)	-
Dividends Paid	(4.82)	-
Finance costs paid	(656.01)	-
C. NET CASH FROM / (USED IN) FINANCING ACTIVITIES	**4,445.45**	**(4,044.17)**
D. NET INCREASE / (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	**5,129.48**	**(20,848.69)**
E. Opening Cash and Cash Equivalents	2,504.58	25,135.66
F. Closing Cash and Cash Equivalents	7,634.06	4,286.96

The accompanying notes are an integral part of the financial statements.
As per report of even date.

For M/s Billimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

CA Akash Mehta
Partner
M.No: 030382
Date: 14.11.2026
Place of Signature : Mumbai

For and on behalf of the Board of Directors

Ravindran Govindan
Chairman and Managing Director
DIN: 03137661

Fischer Medical Ventures Limited

Notes to Financial Statements:

1. The unaudited financial results of the Group for the quarter and half year ended September 30, 2026 have been prepared in accordance with the Indian Accounting Standards ("Indian Accounting Standards ("Ind As") As Prescribed under section 133 of the Companies Act, 2013 as amended.

2. The unaudited financial results of the Group for the quarter/half year ended September 30, 2026 have been reviewed by the audit committee on November 14, 2026 and thereafter Board of directors at their meeting held on November 14, 2026.

3. The Group is primarily engaged in one business segment in accordance with the requirement of Indian Accounting Standards (Ind As) 108: Operating Segment. Accordingly, no separate segment information has been provided.

4. On 28th July, 2025, the Board approved the sub division of Equity shares of Rs. 10/- into 10 equity shares of Re.1 /- each by amending the capital clause of the Memorandum of Association. The shareholder's approval was obtained via postal Ballot on 30th August, 2025. Effective from the record date of 12th September, 2025, the authorized and paid-up share capital of the Company was split accordingly. Earnings Per Share (EPS) for the current and comparative periods has been proportionately adjusted and restated to ensure consistency and comparability.

5. During the quarter, the Company's Board of Directors, through Circular Resolutions dated August 11, August 12, August 13 and August 14 2026, approved the allotment of equity shares upon conversion of convertible warrants, pursuant to the exercise of the conversion option by the respective warrant holders.

   The details of the allotments are as follows:

   • 11 August 2026: The Board approved the allotment of 23,00,000 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹4,03,65,000.

   • 12 August 2026: The Board approved the allotment of 66,31,664 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹11,63,85,703.

   • 13 August 2026: The Board approved the allotment of 1,42,78,217 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by persons belonging to the Promoter and Non-Promoter Categories. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹25,05,82,708.35.

   • 14 August 2026: The Board approved the allotment of 2,05,05,909 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by persons belonging to the Promoter and Non-Promoter Categories. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹35,98,78,702.95.

•17 August 2026: The Board approved, through a circular resolution, the allotment of 4,54,210 equity shares of face value of ₹1 each, at an issue price of ₹23.40 per equity share (including a premium of ₹22.40 per share), upon conversion of an equivalent number of convertible warrants held by a person belonging to the Promoter Category. The allotment was made for cash upon receipt of the balance exercise price of ₹17.55 per warrant, aggregating to ₹79,71,385.50.

6. Figures for the previous periods have been reclassified, wherever necessary, to conform to the current period's classification.

7. Changes in Comparative Figures: -

The consolidated comparative figures for the quarter and half-year ended September 30, 2025, in respect of FMV International Ventures PTE Ltd., Fischer Hospitality Sdn. Bhd., FMV Global Innovations PTE Ltd., PellucidCare Health Innovations Pte Ltd. (formerly known as FMV HealthCare PTE Ltd.) (foreign subsidiaries) and one foreign step-down subsidiary, FMV Technologies Sdn. Bhd., were initially considered based on financial information certified by the respective management, as these subsidiaries were not material individually or in aggregate for the purpose of quarterly consolidation.

Subsequently, the respective component auditors, while completing the annual audit of these foreign subsidiaries for the previous financial year, identified and incorporated certain audit adjustments relating to the financial information of the previous year. These adjustments were made to appropriately reflect the financial information on a quarterly basis and ensure comparability of the financial figures. The component auditors have subsequently provided their review deliverables for Q2 FY 2026-27, incorporating the revised comparative financial figures based on the audited financial information.

Accordingly, the comparative figures for the quarter ended September 30, 2025, and the corresponding half-year period ended September 30, 2025, have been revised in the consolidated financial statements to reflect the financial information provided by the component auditors. Consequently, certain comparative figures previously reported in the consolidated financial statements differ from the corresponding figures presented in the current period.

These revisions arise from the incorporation of audit adjustments identified during the subsequent annual audit of the foreign subsidiaries and do not have any impact on the overall annual profit/(loss) or closing reserves of the Group for the previous financial year.

Details of the revisions are disclosed below for transparency and to facilitate an appropriate understanding and comparison of the financial information.

(Amount in Lakhs)

Particulars	**Variance**	
	Quarter ended September 30, 2025	**Year to Date period ended September 30, 2025**
Sales	(1.01)	9.54
Total Income (A)	**(1.01)**	**9.54**
Cost of Material Consumed	5.67	5.67
Employee Benefit Expenses	-	3.80
Finance Costs	-	0.05
Other Expenses	(1.67)	18.58
Total Expenses (B)	**4.00**	**28.10**
Net Profit (A-B)	**(5.01)**	**(18.55)**